Long-term safety data continues to accumulate, and a comprehensive 2024 review in Diabetes Care by Daniel Drucker concluded that the overall risk-benefit profile of GLP-1 medicines remains favorable for their approved indications
GLP-1 Receptor Agonists and Glucagon/GIP/GLP-1 Receptor Dual or Triple AgonistsMechanism of Action and Emerging Therapeutic Landscape in #MASLD Bruno Ramos Molinas Post GLP-1 Receptor Agonists and Glucagon/GIP/GLP-1 Receptor Dual or Triple AgonistsMechanism of Action and Emerging Therapeutic Landscape in #MASLD
Table 2 Clinical intervention strategies for ferroptosis
Rekkers ME, Aardenburg L, Scheffers M, van Elburg AA, van Busschbach JT (2022) Shifting the focus: a pilot study on the effects of positive body exposure on body satisfaction, body attitude, eating pathology and depressive symptoms in female patients with eating disorders
Patients with certain variants may experience more initial nausea but often benefit from microdose approaches or specific formulations
Research suggests BPC-157 may influence: Angiogenesis (formation of new blood vessels) Cellular signaling pathways Tissue repair mechanisms Inflammatory responses These findings are promising but should be interpreted cautiously
